Protagonist Therapeutics, Inc.
NASDAQ:PTGX
41.49 (USD) • At close December 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Protagonist Therapeutics, Inc. |
Symbool | PTGX |
Munteenheid | USD |
Prijs | 41.49 |
Beurswaarde | 2,472,721,020 |
Dividendpercentage | 0% |
52-weken bereik | 21.43 - 48.89 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Dinesh V. Patel Ph.D. |
Website | https://www.protagonist-inc.com |
An error occurred while fetching data.
Over Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)